Overview

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT)

Status:
Not yet recruiting
Trial end date:
2023-10-23
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in participants with pre-diabetes (pathological Oral Glucose Tolerance Test (OGTT)).
Phase:
Phase 2
Details
Lead Sponsor:
Aphaia Pharma US LLC